Jardiance (empagliflozin) offers benefits that extend well beyond blood sugar control. Originally approved as a diabetes medication, it has since proven effective for heart failure and chronic kidney disease, making it one of the more versatile medications in modern cardiology and endocrinology. Its benefits span at least four major areas: blood sugar reduction, cardiovascular protection, kidney preservation, and modest improvements in weight and blood pressure.
How Jardiance Works
Your kidneys filter roughly 180 grams of glucose from your blood every day, then reabsorb nearly all of it back into your bloodstream. A protein called SGLT-2, located in the early segments of the kidney’s filtering tubes, handles about 90% of that reabsorption. Jardiance blocks this protein, preventing it from recapturing glucose. The result: excess glucose passes into your urine instead of cycling back into your blood.
This mechanism is fundamentally different from most diabetes drugs. Rather than forcing your pancreas to produce more insulin or making your cells more sensitive to it, Jardiance works through the kidneys. That independence from insulin is part of why it carries a low risk of causing dangerously low blood sugar on its own. Because the drug also reduces sodium reabsorption in the kidneys, it has a mild diuretic-like effect that contributes to its blood pressure and heart failure benefits.
Blood Sugar Reduction
Jardiance is taken once daily in the morning, with or without food, starting at 10 mg. If tolerated, the dose can be increased to 25 mg. Both doses lower HbA1c, the measure of average blood sugar over the previous two to three months. The blood sugar benefit depends directly on how well your kidneys are filtering, so the drug becomes less effective for glucose control when kidney function drops below a certain threshold. For patients with significantly reduced kidney filtration (eGFR below 30), Jardiance is not recommended for blood sugar management specifically, though it may still be prescribed for heart or kidney protection.
Cardiovascular Protection
The cardiovascular benefits of Jardiance are among the most well-documented of any diabetes medication. The landmark EMPA-REG OUTCOME trial, which studied patients with type 2 diabetes who already had cardiovascular disease, found that adding Jardiance to standard care reduced cardiovascular death by 38%, all-cause death by 32%, and hospitalization for heart failure by 35%. The composite risk of a major cardiovascular event (heart attack, stroke, or cardiovascular death) dropped by 14%.
These are large, clinically meaningful reductions. The heart failure benefit in particular was striking and prompted researchers to test Jardiance in heart failure patients who didn’t necessarily have diabetes.
Heart Failure Benefits
Jardiance is now approved to treat heart failure regardless of whether someone has diabetes. The EMPEROR-Reduced trial studied patients whose hearts had weakened pumping ability and found that Jardiance reduced the combined risk of cardiovascular death or hospitalization for heart failure from 24.7% to 19.4%, a 25% relative risk reduction. Separate trials confirmed benefits in patients whose hearts pump normally but stiffen and don’t fill properly, a condition called heart failure with preserved ejection fraction that historically had very few effective treatments.
For heart failure patients, the drug appears to work through several mechanisms at once: reducing fluid overload through its diuretic-like action, lowering the workload on the heart by decreasing blood pressure, and potentially improving how heart muscle cells use energy. The benefit shows up relatively quickly, with separation from placebo visible within the first few months of treatment.
Kidney Protection
The EMPA-KIDNEY trial demonstrated that Jardiance reduced the risk of kidney disease progression or cardiovascular death by 28% compared to placebo in people with chronic kidney disease. This benefit held across a broad range of patients, including those with and without diabetes.
The kidney-protective effect likely stems from Jardiance reducing pressure inside the kidney’s filtering units. By blocking glucose and sodium reabsorption early in the kidney tubule, the drug triggers a feedback mechanism that constricts the blood vessel feeding each filter, lowering the pressure inside it. Over time, this reduced pressure slows the scarring and damage that drive chronic kidney disease forward. This is a meaningful benefit for a condition that previously had limited treatment options and often progressed to dialysis.
Weight Loss and Blood Pressure
Because Jardiance causes your body to excrete glucose through urine rather than store it, you lose calories. This translates to modest but consistent weight loss. At the 10 mg dose, patients lost roughly 2.8% of their body weight, which works out to about 5.6 pounds for someone weighing 200 pounds. The 25 mg dose produced about 3.2% weight loss, or roughly 6.4 pounds for the same person. This isn’t dramatic weight loss, but it’s a welcome secondary benefit for a medication primarily prescribed for other reasons.
Blood pressure also drops modestly. The 10 mg dose reduced systolic blood pressure (the top number) by about 2.6 mmHg compared to placebo, while the 25 mg dose reduced it by about 3.4 mmHg. Again, this is a mild effect on its own, but for someone already on blood pressure medications, even a few points of additional reduction can matter.
Common Side Effects to Expect
The mechanism that makes Jardiance effective, flushing glucose into the urine, also creates a sugar-rich environment that yeast and bacteria can exploit. Genital yeast infections are the most notable side effect. In clinical trials, about 5.4% of women on the 10 mg dose developed genital fungal infections compared to 1.5% on placebo. For men, the rate was 3.1% on the 10 mg dose versus 0.4% on placebo. These infections are typically mild and treatable, but they’re common enough that you should be aware of them.
Urinary tract infections showed a more modest increase. In pooled trial data, the overall rate was 9.3% on the 10 mg dose compared to 7.6% on placebo. When broken down by sex, women experienced UTIs at rates of 16.6% to 18.4% across groups, while men saw rates of 3.2% to 4.1%. The difference between Jardiance and placebo was relatively small for UTIs, but staying well-hydrated and maintaining good hygiene helps reduce the risk.
Increased urination is expected given the drug’s mechanism. Some people notice it more in the first few weeks as their body adjusts. Dehydration and related dizziness can occur, particularly in older adults or those already taking diuretics.
Who Gets the Most Benefit
Jardiance occupies an unusual position in that it benefits three overlapping but distinct patient groups. People with type 2 diabetes get blood sugar control plus cardiovascular and kidney protection. Heart failure patients, even without diabetes, get reduced hospitalizations and improved outcomes. And people with chronic kidney disease get slower disease progression. Many patients fall into more than one of these categories, which means a single medication addresses multiple problems simultaneously.
The cardiovascular and kidney benefits are especially valuable because they represent actual reductions in death and disease progression, not just improvements in lab numbers. Many diabetes medications lower blood sugar effectively without demonstrating that they prevent heart attacks or protect kidneys. Jardiance does both, which is a major reason it has become a first-line consideration for patients with type 2 diabetes who have cardiovascular disease or kidney disease risk factors.